This agent recently achieved an additional indication to reduce myocardial infarction, stroke, coronary revascularization, and cardiovascular death risk in adult patients with ASCVD.
Janus kinase inhibitors effectively treat rheumatoid arthritis, but their use in smokers aged older than 65 years and certain other populations potentiates the risk of adverse events.
Newer drugs are more targeted than standard agents, but their incorporation into treatment regimens is challenging because of the risk of cardiovascular and infectious adverse events.